Literature DB >> 3317728

Mycoses caused by Candida lusitaniae.

T L Hadfield1, M B Smith, R E Winn, M G Rinaldi, C Guerra.   

Abstract

Candida lusitaniae, a fungus with a low incidence of infection in immunocompetent people, is emerging as an opportunistic pathogen in immunocompromised hosts. This yeast is generally resistant to amphotericin B and may present therapeutic difficulties. C. lusitaniae may be misidentified as one of several other fungal species, including Candida tropicalis, Candida parapsilosis, and even Saccharomyces cerevisiae. As judged by in vitro antifungal susceptibility testing, minimal inhibitory concentrations of antifungal agents other than amphotericin B are achievable, but fungicidal levels are not. When encountered in blood or other body sites, C. lusitaniae should be carefully considered as a potential pathogen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317728     DOI: 10.1093/clinids/9.5.1006

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  43 in total

1.  Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.

Authors:  Carolina Rodrigues Costa; Janine Aquino de Lemos; Xisto Sena Passos; Crystiane Rodrigues de Araújo; Ana Joaquina Cohen; Lúcia Kioko Hasimoto E Souza; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2006-07       Impact factor: 2.574

2.  Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species.

Authors:  Chien-Ching Hung; Yun-Liang Yang; Tsai-Ling Lauderdale; L Clifford McDonald; Chin-Fu Hsiao; Hsiao-Hsu Cheng; Yong An Ho; Hsiu-Jung Lo
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Rapid identification of Candida species by DNA fingerprinting with PCR.

Authors:  M Thanos; G Schonian; W Meyer; C Schweynoch; Y Graser; T G Mitchell; W Presber; H J Tietz
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Nosocomial Candida glabrata colonization: an epidemiologic study.

Authors:  J A Vazquez; L M Dembry; V Sanchez; M A Vazquez; J D Sobel; C Dmuchowski; M J Zervos
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

5.  Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.

Authors:  G St-Germain; M Laverdière; R Pelletier; A M Bourgault; M Libman; C Lemieux; G Noël
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 6.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

7.  Candida lusitaniae causing fatal meningitis.

Authors:  P S Sarma; P Durairaj; A A Padhye
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

8.  In vitro activity of a new polyene, SPA-S-843, against yeasts.

Authors:  C Rimaroli; T Bruzzese
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

10.  Prosthetic valve endocarditis caused by Candida lusitaniae, an uncommon pathogen: a case report.

Authors:  Ross G Michel; Gary T Kinasewitz; Douglas A Drevets; Jeremy H Levin; Douglas W Warden
Journal:  J Med Case Rep       Date:  2009-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.